Glenmark Pharmaceuticals Inc., USA launches Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single-Dose Vial

Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch1 of Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) SingleDose Vial. Glenmark's Methylene Blue Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, ProvayBlue®2 Injection, 50 mg/10 mL (5 mg/mL), of Provepharm SAS [NDA 204630].

According to IQVIA® sales data for the 12-month period ending April 2026, the ProvayBlue® Injection, 50 mg/10 mL (5 mg/mL) market3 achieved annual sales of approximately $19.0 million*.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, "The launch of Methylene Blue Injection USP reflects Glenmark's ongoing commitment to expanding access to quality, affordable medicines for healthcare institutions and the patients they serve. This addition further strengthens our institutional portfolio and reinforces our focus on delivering reliable treatment options across the U.S. market."

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 2156.80 as compared to the previous close of Rs. 2155.60. The total number of shares traded during the day was 16226 in over 944 trades.

The stock hit an intraday high of Rs. 2171.55 and intraday low of 2133.50. The net turnover during the day was Rs. 34905512.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 USA MethyleneBlueInjection